Global Health Ltd
Global Health Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Continued strong volume growth with 25%+ growth expected in next 5-6 quarters (FY27). Medanta is delivering strong growth with recent quarterly revenue up 25% YoY and EBITDA growing 17-27% YoY across various hospital clusters.
From Global Health Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Continued strong volume growth with 25%+ growth expected in next 5-6 quarters (FY27).
- Developing hospitals like Lucknow (6.5 years old) and Patna (4.5 years old) showing robust 30%+ year-on-year growth in volume and revenue.
- Significant bed additions planned: ~500 beds with minimal capex in existing hospitals and ~2,700 beds via 5 greenfield projects over next 3-4 years.
- Robust ARPOB growth expected, driven by complexity scaling, specialty additions (e.g., robotics, transplants), and tariff increases at appropriate times.
- Procedural additions planned: ~10 new operation theaters, cath labs, and minimally invasive surgeries.
- Noida unit ramping up with empanelments driving occupancy and revenues upwards.
- Growth lever also from expansion into new markets and services (e.g., oncology in Indore, new specialties in Noida).
2 more points from Global Health Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Global Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex guidance: INR 800-900 crore
- FY28 capex estimate: INR 600-700 crore
- Plans to add approximately 500 beds across existing hospitals in the short term with minimal capex
- Approximately 2,700 beds to be added through 5 greenfield projects over next 3-4 years, total 5-year project capex ~INR 45,000 million
- Capital plan supported by internal accruals and project-specific debt
- Focus on operational expansions: adding ~10 operation theaters across existing hospitals in FY27
- Noida hospital expansion ongoing, alongside specialty additions
2 more points from Global Health Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Global Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Global Health Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Global Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.2K Cr, net profit ₹142 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Global Health Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Suven Life Scie. (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnos. (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnos.'s Q4 FY26 earnings…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
- Gaudium IVF and Women Health Ltd (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
Arthneeti Pro · Annual
Global Health Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Global Health Ltd Q4 FY26 results?
Continued strong volume growth with 25%+ growth expected in next 5-6 quarters (FY27). Medanta is delivering strong growth with recent quarterly revenue up 25% YoY and EBITDA growing 17-27% YoY across various hospital clusters.
What is Global Health Ltd share price analysis?
Global Health Ltd currently shows a neutral. The stock trades at a P/E of 66.2 with a market cap of ₹37,919 Cr. Investors should review the full earnings analysis for detailed insights.
Is Global Health Ltd planning capital expenditure?
FY27 capex guidance: INR 800-900 crore - FY28 capex estimate: INR 600-700 crore - Plans to add approximately 500 beds across existing hospitals in the short term with minimal capex - Approximate
Keep Global Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.